Fighting Cancer Every Step of the Way™

Vigilant Biosciences is transforming the early detection and intervention of cancer.

Learn More
Media Kit

Introducing the OraMark™ Laboratory Developed Test for the U.S!

Learn More about OraMark™
vb-homepage-image3

Dedicated to Early Intervention. And Life.™


Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. The OncAlert™ Oral Cancer product line uses patented technology based on clinical science that shows possible presence of oral cancer in its earliest stages… even before visual or physical symptoms develop.

Learn More
Did You Know?

When diagnosed early, oral cancer patients have an 80 to 90% survival rate.

Unfortunately, over 40% of those diagnosed with oral cancer will die within five years due to these cases being discovered as a late stage malignancy.

Learn More

At A Glance

Transforming Early Detection

Vigilant Biosciences™ products are based on patented technology that detects specific protein markers clinically shown to aid in the detection of early stage cancers, even prior to observation of visual or physical symptoms... more


Easy-to-Use and Non-Invasive

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more


Accurate and Objective Results at the Point-of-Care or in the Laboratory

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more

MORE ABOUT VIGILANT'S ONCALERT™ TECHNOLOGY

News + Press

  • sunsentinel

    Fort Lauderdale biotech receives small-business research grant

    Fort Lauderdale-based Vigilant Biosciences announced Thursday it has received a Small Business Innovation Research grant for more than $200,000 from the National Institute of Dental and Craniofacial Research. The 15-month grant will finance research to develop a diagnostic test that…more

  • vb-400x210

    Vigilant Biosciences Awarded Phase I SBIR Grant for Next Generation Oral Cancer Diagnostic System

    FORT LAUDERDALE, Fla. – Aug 11, 2016 – Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced that it has received a Phase I Small Business Innovation…more

  • MH-logo2

    Head, neck cancer’s global challenge

    Head and neck cancer is a growing challenge with more than 650,000 new cases and more than 360,000 deaths worldwide each year. Historically, the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. More…more

  • vb-400x210

    Vigilant Biosciences Announces Oral Presentation on CD44 and Associated Markers in Oral Rinses and Tissues from Oral Cancer Patients at AHNS 9th International Conference on Head and Neck Cancer

    FORT LAUDERDALE, Fla. and SEATTLE, AHNS Conference – July 13, 2016 – Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced a presentation of data related to…more


©2011-2016 Vigilant Biosciences, Inc. All Rights Reserved.

×